Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Olanzapine treatment for dopaminergic‐induced hallucinations

Ondo, William G., Levy, Joel K., Vuong, Kevin Dat, Hunter, Christine, Jankovic, Joseph·2002·Movement Disorders

Abstract

Atypical antipsychotic medications with lower affinities for D2 receptors are considered useful alternatives to treat drug‐induced hallucinations in Parkinson's disease (PD). We conducted a double‐blind, placebo‐controlled, unforced titration, parallel design study (2:1 drug to placebo randomization ratio) using olanzapine (2.5–10 mg/day to effect) in 30 PD patients with drug‐induced hallucinations. We performed an extensive battery of neuropsychological tests, the Unified Parkinson's Disease Rating Scale (UPDRS), assessments of on and off time at baseline and at 9 weeks after starting the medication. Sixteen patients on olanzapine (mean dose, 4.6 mg/night) and 11 on placebo completed the study. Compared with placebo, performance on the UPDRS item 2 (thought disorder), and a structured interview for hallucinations, both tended to improve on drug but neither reached statistical significance. A neuropsychological test battery did not show any significant differences. Total on UPDRS motor scores (P < 0.05) and timed tapping (P < 0.01) worsened while on drug compared to placebo. Bradykinesia (P < 0.01) and gait (P < 0.001) items on the UPDRS largely accounted for this deterioration. After completion of the study, 8 of 16 patients randomly assigned to drug continued olanzapine at a mean dose of 2.4 mg/day. However, at the last recorded visit only 5 of 24 (20.8%) of all patients exposed to drug (including those originally randomly assigned to placebo) remained on olanzapine. In patients with PD, low‐dose olanzapine did not significantly improve hallucinations but did worsen motor function. © 2002 Movement Disorder Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.10217

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 172

Metadata

Authors
Ondo, W. G., Levy, J. K., Vuong, K. D., Hunter, C., & Jankovic, J.
Venue
Movement Disorders
Publisher
Wiley
Published
2002-09
Volume
17
Issue
5
Pages
1031-1035
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W2033871682
Cited by
172
References
1
FWCI
5.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.